Again, in direct contrast, there was no effect of HIF-2α positivity on cancer-specific survival (log-rank test χ2=2.275, d.f.=1, HR=0.545, 95% CI: 0.244–1.217, P=0.139; Figure 8A), although, contrary to HIF-1α, a trend towards decreased recurrence (log-rank test χ2=2.51, d.f.=1, HR=0.542, 95% CI=0.25–1.17, P=0.12) was observed for HIF-2α positivity (Figure 8B). This evidence concerns the gene EPAS1 and cancer.